CNBX (CNBX Pharmaceuticals) EPS (Basic): $0.00 (TTM As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is CNBX Pharmaceuticals EPS (Basic)?

CNBX Pharmaceuticals CNBX +33.33% EPS (Basic) is $0.00 as of May. 2026. The stock has 3 warning signs investors should review.

CNBX Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in May. 2026 was $0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in May. 2026 was $0.00.

CNBX Pharmaceuticals's EPS (Diluted) for the three months ended in May. 2026 was $0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in May. 2026 was $0.00.

CNBX Pharmaceuticals's EPS without NRI for the three months ended in May. 2026 was $0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in May. 2026 was 0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

CNBX Pharmaceuticals  (OTCPK:CNBX) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

CNBX Pharmaceuticals EPS (Basic) Related Terms

CNBX Pharmaceuticals EPS (Basic) Historical Data

* Premium members only.

The historical data trend for CNBX Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CNBX Pharmaceuticals EPS (Basic) Chart

CNBX Pharmaceuticals Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.40 -3.59 -0.42 -0.02 0.00

CNBX Pharmaceuticals Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CNBX Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

CNBX Pharmaceuticals's Basic EPS for the fiscal year that ended in Aug. 2025 is calculated as

Basic EPS (A: Aug. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-0.314-0)/90.649
=-0.00

CNBX Pharmaceuticals's Basic EPS for the quarter that ended in May. 2026 is calculated as

Basic EPS (Q: May. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-0.154-0)/1318.594
=-0.00

EPS (Basic) for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $0.00 mean?
CNBX Pharmaceuticals (CNBX) has a EPS (Basic) of $0.00 as of May. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on CNBX Pharmaceuticals and its competitors.
Is CNBX Pharmaceuticals' EPS (Basic) too high?
CNBX Pharmaceuticals' current EPS (Basic) is $0.00.
How does CNBX Pharmaceuticals' EPS (Basic) compare to SIGY and LIPO?
CNBX Pharmaceuticals' EPS (Basic) of $0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on CNBX Pharmaceuticals and its competitors. CNBX Pharmaceuticals's current EPS (Basic) is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CNBX Pharmaceuticals stock overvalued right now?
CNBX Pharmaceuticals (CNBX) has a current EPS (Basic) of $0.00. The current EPS (Basic) is $0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For CNBX Pharmaceuticals (CNBX), the current EPS (Basic) is $0.00 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CNBX Pharmaceuticals Business Description

Address No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814
CNBX Pharmaceuticals Inc is a clinical-stage biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the Cannabics SR, an oral capsule developed for the treatment of patients with cancer and cancer anorexia cachexia syndrome (CACS). It also has an anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) named RCC-33.